Cervical cancer is the fourth most common cancer in women world-wide and the most common cancer in many low-and middle-income countries. 1 It is estimated that 84% of cervical cancer cases occur in less developed countries, where cervical cancer diagnostic screening and prevention methods are limited. To illustrate this disparity, Over time, the incidence of cervical cancer in developed markets has been reduced thanks to the use of Pap smears (Pap test) and subsequent treatments, but women living in rural areas and low-resource settings (LRS) worldwide lack access to these relatively straightforward lifesaving techniques, and the demands of the test are too complex for many low-resource countries. Based on this background, the critical role for
1679a. Misrahi. Results. https://doi.org/10.30953/tmt.v1. 81 Page 2 of 10 telemedicine as a platform for achieving quality controlled, accessible screening for cancer of the cervix becomes clear. VIA is practiced by health providers in over 70 countries around the world, and has been studied and debated extensively as a high patient acceptance, low-cost screening alternative.
Test Sensitivity
In one systematic review and meta-analysis, the authors reported that regarding the The authors concluded, "Although differences in sensitivity between tests could be interpreted as large, absolute differences in missed diagnoses were small. By contrast, small differences in specificity resulted in fairly large absolute differences in overtreatment." 4 
Patient Acceptance
In clinical use, VIA is well accepted by patients. One study of women in Morocco revealed low awareness of cervical cancer (19.6%) and a high acceptability of VIA screening (94.5%). Among the 306 women screened, 99% stated they would recommend the VIA testing to their friends and female relatives.
All women who were screened negative expressed their intent to repeat the test every three years. Those found VIA-positive affirmed they would perform confirmatory explorations. Almost all (96.3%) of the women believed that screening by VIA could save their lives; cervical cancer was a concern for 98.6%. There were 11.6% who felt anxious about repeating the VIA test. The majority of women (98.6%) were satisfied with the service received at the health center. 5 
Cost
In a cost comparison of conventional cytology (Pap), VIA, and HPV DNA testing for detecting cases of cervical intraepithelial neoplasia grade 2+ (CIN2+) among HIVinfected women currently taking antiretroviral treatment at a public HIV clinic in Johannesburg, South Africa, it was reported that VIA was least costly.
Colposcopic biopsy costs largely drove the total and per case costs on average $67.71
per procedure. In a higher volume scenario, the average cost per procedure was $3.67
for VIA, $8.17 for Pap and $54.34 for HPV DNA.
VIA was least sensitive but most cost-effective at $17.05 per true CIN2+ case detected. Enhanced Visual Assessment (EVA)
Ultimately, the success of any screening method requires convenient, cost-effective accessibility by a clinician who is qualified to perform the procedure and interpret the findings. Existing technology tends to be large and bulky, expensive, and not cloudconnected. It requires constant electricity supply and an expert colposcopist to be available at all times.
As a result, visual inspection of the cervix has emerged as a screening tool for LRS despite its limited specificity. This is because it provides immediate results, is accepted by patients, and is economical. 
EVA in Clinical Practice
In Kenya, as part of a cervical cancer screening camp, six organizations conducted cervical cancer screening using the EVA System. 7 
